Clinical Trials Browser

Phase 1 × INDUSTRY × COVID-19 × Clear all

COVID-19, Neoplasms, Korsakoff Syndrome

NCT06469138 2025-01-29

8479217

CNSDermatologicGastrointestinalMyeloidOther hematologic neoplasmOther solid neoplasmThoracic

Mesothelioma, Malignant, COVID-19, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Myelodysplastic Syndromes, Pancreatic Neoplasms, Leukemia, Myeloid, Acute

NCT04803227 2022-01-04

Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19

Phase 1 Terminated

13 enrolled

Lymphoid

COVID-19, Lymphoma, Follicular

NCT04419623 2021-05-12

A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

Phase 1 Completed

7 enrolled

Other hematologic neoplasm

COVID-19, Carcinoma, Neoplasms, Hematologic Neoplasms

NCT04564040 2020-12-29

A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole

Phase 1 Completed

20 enrolled

Lymphoid

COVID-19, Lymphoma, Mantle-Cell

Clinical Trials

BOOST

8479217

Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19

A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole